Searched for
PFIZER OBESITY DRUG
Pfizer CFO Dave Denton to leave company in AugustPfizer's finance chief Dave Denton is leaving on August 15. Cecile Guegan will be the interim chief financial officer. Denton's departure r...- Global drugmakers rush to boost US presence as tariff threat loomsGlobal drug companies are boosting U.S. production and stockpiling medicines. This is a response to potential tariffs on branded drugs. Com...
- From oncology to obesity, Pfizer bets big on India for its next growth wavePfizer is prioritizing India for future growth. The company plans to launch new medicines here soon after their global release. Pfizer aims...
- Eli Lilly brings monthly Alzheimer's therapy donanemab to India at ₹91,688 per vialEli Lilly is making Alzheimer's a major focus for its future innovations. The company is also expanding its specialty medicine offerings in...
- Weight-loss drug semaglutide set to get cheaper as generic wave builds in IndiaPrices for generic semaglutide, a popular weight-loss drug, are expected to fall by more than half in the coming months. This sharp decline...
- Chinese medicines bring relief to India’s cancer patientsIndia’s cancer treatment landscape is seeing a shift as lower-cost immunotherapy drugs developed in China and marketed through Indian partn...
- US market today: Pfizer posts strong first-quarter, sees boost from recent legal winsPfizer reported higher-than-expected sales and profit on Tuesday and said a patent extension for its Vyndamax heart drug and a recent favor...
- US Stocks | Kailera soars over 60% in Nasdaq debut as weight-loss drug race heats upKailera Therapeutics shares surged 62.5% in their Nasdaq debut after raising $625 million in a U.S. IPO priced at the top end of its range....
- Why is PFE stock falling today despite beating Pfizer's earnings estimates? Key factors investors are watchingPFE stock today: Pfizer's stock dipped despite strong fourth-quarter earnings. Investors reacted to the company's modest 2026 outlook. Decl...
- Weight-loss treatment: How has obesity medicine market become battleground for pharma giants like Pfizer, AstraZeneca, Eli Lilly?Obesity, weight-loss medicines: Novo has been scrambling to keep pace in the obesity drug race it started, losing ground to rival Eli Lilly...
- Metsera accepts Pfizer's $10 billion bid in ongoing M&A battleMetsera has accepted Pfizer's $10 billion acquisition offer. This ends a bidding war with rival Novo Nordisk. Pfizer will pay $86.25 per sh...
- Pfizer weighs sweeter offer for Metsera after Judge blocks bid to halt Novo Nordisk’s $10 billion takeoverPfizer is increasing its offer for Metsera. This comes after a judge rejected Pfizer's attempt to stop rival Novo Nordisk's bid. Pfizer's d...
- Pfizer, Novo Nordisk escalate bidding war for obesity drug developer MetseraA fierce bidding war is underway for Metsera, an obesity drug developer. Novo Nordisk has made a $10 billion offer, which Metsera considers...
- Pfizer sues Metsera, Novo Nordisk over rival obesity drug bidPfizer sued Metsera and Novo Nordisk, alleging Metsera breached its merger agreement by deeming Novo's $8.5 billion bid superior. Pfizer se...
- PFE stock rises 5.3% today: Pfizer seals Trump drug price deal with $70 billion U.S. investment and $7.3 billion Metsera weight-loss acquisitionPfizer Inc. (NYSE: PFE) experienced a significant uptick in its stock price following two major announcements on September 30, 2025. Presid...
- Pfizer PFE stock, Metsera MTSR stock: Pfizer, Metsera share prices jump as deal worth over $7 billion gets thumbs upStock Market boom for both companies' shares came as Pfizer said on Monday it would acquire drug developer Metsera in a deal valued at up t...
- Pfizer closes in on $7.3 billion takeover of anti-obesity drugmaker Metsera: ReportPfizer is close to acquiring Metsera, an anti-obesity drug developer. The deal could be worth $7.3 billion. Pfizer will pay $47.50 per shar...
- Pfizer scraps weight loss pill after liver injury: What it means for the future of obesity drugs?Pfizer halted development of its weight-loss pill, danuglipron, after liver injury concerns surfaced during trials, impacting its ambition ...
- Pfizer ends development of weight-loss pill danuglipronPfizer has halted the development of its experimental weight-loss pill, danuglipron, following a trial participant's liver injury, which re...
- Pfizer shifts focus to cancer and biotech drugsPfizer Inc. is shifting its research focus to diseases that have high potential for big profits and for treatment improvements, such as can...
Load More
